A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by Svetlana up on 2024-5-29
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Clinical treatment Clinical treatment,clinical treatment
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Parkinson's disease (PD) patients treated with levodopa only (PD_L)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Parkinson's disease (PD) patients treated with both levodopa and Entacapone, a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 13
- Group 1 sample size Number of subjects in the case (exposed) group
- 11
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4-V5
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- T-Test
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- Matched on Factors on which subjects have been matched on in a case-control study
- age, sex
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2024-5-29
Source: Figure 3, text
Description: Genera significantly different in abundance in Parkinson's disease patients treated with levodopa only (PD_L) versus Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE).
Abundance in Group 1: increased abundance in Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacterium | ||
| Eubacterium | ||
| Christensenellaceae R-7 groupChristensenellaceae R-7 group |
Revision editor(s): Fiddyhamma, Scholastica
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2024-5-29
Source: Figure 3, text
Description: Genera significantly different in abundance in Parkinson's disease patients treated with levodopa only (PD_L) versus Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE).
Abundance in Group 1: decreased abundance in Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia | ||
| Dorea | ||
| Faecalibacterium | ||
| Intestinibacter | ||
| Lactobacillus | ||
| Sellimonas |
Revision editor(s): Fiddyhamma, Scholastica
